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OBJECTIVES The goal of this study was to determine the long-term effects of statins and antioxidant
vitamins on flow-mediated vasodilation of the brachial artery in older adults with hypercho-
lesterolemia.
BACKGROUND Lipid-lowering therapy and antioxidant vitamins improve endothelium-dependent vasodila-
tion in young and middle-aged adults with hypercholesterolemia, but their effects in older
adults are not known.
METHODS Two double-blind, placebo-controlled studies were performed in individuals 70 years old
with low-density lipoprotein cholesterol (LDL-C)140 mg/dl. In the first study, 37 subjects
were randomized to receive (group 1) pravastatin for six months then pravastatin and vitamin
E for six additional months or (group 2) vitamin E for six months, then pravastatin and
vitamin E for six additional months. In the second study, additional 17 subjects sequentially
received simvastatin for six months, then simvastatin and vitamins C and E for six additional
months. Flow-mediated vasodilation of the brachial artery was measured by high-resolution
ultrasound.
RESULTS At baseline, subjects in both studies were similar in age (mean  SD, 75.8  4.2 years),
gender, systolic blood pressure, total cholesterol (261.6  37.4 mg/dl), LDL-C (180.3 
28.1 mg/dl), high-density lipoprotein cholesterol and triglycerides levels. Flow-mediated
vasodilation was severely impaired (2.2 3.9%). Both statins reduced total and LDL-C levels
(p  0.001); however, neither statin, antioxidant vitamin regimen nor the combination of
statins and antioxidant vitamins improved flow-mediated vasodilation of the brachial artery.
At baseline, nitroglycerin-mediated vasodilation also was impaired (10.7 5.6%) and did not
change in either study.
CONCLUSIONS Older adults with hypercholesterolemia have impaired flow-mediated vasodilation of the
brachial artery that does not improve after one year of therapy with statins and antioxidant
vitamins, despite significant lipid-lowering. (J Am Coll Cardiol 2001;38:1806–13) © 2001
by the American College of Cardiology
Coronary heart disease (CHD) is the leading cause of death
in older men and women (1). Endothelial dysfunction
contributes to the initiation, perpetuation and clinical man-
ifestations of CHD (2–4). Normally, increased blood flow
raises shear stress on endothelial cells, leading to nitric
oxide-dependent arterial dilation; however, in patients with
atherosclerosis or CHD risk factors, endothelial dysfunction
leads to impaired flow-mediated vasodilation (FMD) or
paradoxical vasoconstriction in response to increased blood
flow (3–5). Flow-mediated vasodilation of the brachial and
coronary arteries are correlated strongly and predict future
adverse cardiovascular events (3,6–9).
Aging is associated with increased endothelial production
of oxygen-derived free radicals that inactivate nitric oxide
leading to impaired endothelium-dependent vasodilation,
independent of coronary risk factors (10–15). Although
lipid-lowering therapy and use of antioxidant vitamins may
improve endothelial function in young and middle-aged
adults (16–22), most studies investigating their effects had a
short duration, did not control for multiple comparisons and
did not include patients70 years old. Furthermore, several
studies have not demonstrated an improvement in endothe-
lial function with these interventions, even in younger
patients (23–28), so the long-term effects of lipid-lowering
therapy and antioxidant vitamins on endothelial function in
older adults are not known.
Two double-blind, placebo-controlled studies evaluated
the long-term effects of lipid-lowering and antioxidant
vitamin therapies in older adults with hypercholesterolemia.
The first study (Pravastatin and Vitamin E in Seniors study
[PAVES]) used pravastatin and vitamin E, alone and in
combination. The second study (Simvastatin, Ascorbate and
Vitamin E in Seniors study [SAVES]) used simvastatin and
vitamins C and E. This study provides complimentary and
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incremental information. The results of these studies are
presented separately and in a combined analysis.
METHODS
Subjects. The Institutional Review Board of the University
of Wisconsin Medical School approved both studies. All
subjects provided informed consent before participation.
Adults 70 years old with fasting low-density lipoprotein
cholesterol (LDL-C) levels 140 mg/dl and triglycerides
levels 350 mg/dl were recruited using mailings to physi-
cians, television promotions and newspaper advertisements.
Excluded were current users of tobaccos, cyclosporine or
warfarin and subjects with elevated serum aspartate amino-
transferase, alanine aminotransferase or creatine kinase lev-
els 3 times the upper limit of normal. Subjects were not
allowed to take cholesterol-lowering medications or vitamin
supplements for four weeks before enrollment or during the
studies, except as prescribed by the research protocol.
Coronary heart disease was defined as a history of myocar-
dial infarction, percutaneous or surgical coronary artery
revascularization or current angina. Hypertension was de-
fined as a systolic blood pressure 140 mm Hg or current
use of antihypertensive medication. Diabetes mellitus was
defined as a history of diabetes mellitus or use of an
antiglycemic medication.
Study designs. In both studies, subjects were counseled
regarding a National Cholesterol Education Program step 1
diet and were given statin-placebo capsules on enrollment
(Fig. 1). After eight weeks of placebo run-in, fasting serum
lipids were remeasured. Adherence was measured by pill
counts, and a minimum compliance rate of 80% was
required for continued participation. If the LDL-C re-
mained 140 mg/dl and the subject was adherent, they
were given active therapy.
Study 1—PAVES. This was a double-blind, randomized,
placebo-controlled, crossover study (Fig. 1). After the
pravastatin-placebo run-in, subjects were randomized to
receive (group 1) pravastatin, 20 mg, each night for 26
weeks followed by pravastatin, 20 mg, and vitamin E,
400 IU (all d-alpha-tocopheryl), each night for an addi-
tional 26 weeks. Subjects in group 2 received vitamin E,
400 IU, and pravastatin-placebo nightly for 26 weeks,
followed by vitamin E, 400 IU, and pravastatin, 20 mg,
nightly for an additional 26 weeks.
Study 2—SAVES. This was a double-blind, placebo-
controlled, sequential treatment study (Fig. 1). After the
simvastatin-placebo run-in, subjects received simvastatin,
20 mg, each night for 26 weeks followed by simvastatin,
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHD  coronary heart disease
FMD  flow-mediated vasodilation
HDL-C  high-density lipoprotein cholesterol
LDL-C  low-density lipoprotein cholesterol
NTG  nitroglycerin
NTGMD  nitroglycerin-mediated vasodilation
PAVES  Pravastatin and Vitamin E in Seniors study
SAVES  Simvastatin, Ascorbate and Vitamin E in
Seniors study
Figure 1. Study designs. PAVES  Pravastatin and Vitamin E in Seniors study; SAVES  Simvastatin, Ascorbate and Vitamin E in Seniors study.
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20 mg, vitamin C, 1,000 mg, and vitamin E, 400 IU (all
d-alpha-tocopheryl), nightly for an additional 26 weeks.
Laboratory measurements. Subjects fasted for at least 12 h
before laboratory tests. Lipid levels, liver function tests and
creatine kinase levels were measured on a Hitachi 747
analyzer using standard reagents (Roche Diagnostics, Indi-
anapolis, Indiana). Total serum cholesterol was measured by
a cholesterol ester/oxidase enzymatic procedure. High-
density lipoprotein cholesterol (HDL-C) was measured
directly using enzymatic colorimetrics incorporating poly-
ethylene glycol-modified cholesterol ester oxidase. Serum
triglycerides were measured using a glycerol kinase-based
enzymatic procedure. Low-density lipoprotein cholesterol
was calculated by the Friedewald formula (29).
Brachial artery reactivity protocol. B-mode ultrasound
was used to measure FMD of the brachial artery (30,31).
Studies were performed at baseline and at subsequent visits
on the morning of phlebotomy, after a 12-h fast. Subjects
took their morning doses of prescribed medications. Bra-
chial artery diameters and blood flows were measured with
a 7.5-MHz linear array vascular ultrasound transducer and
an Agilent Technologies 5500 Sonos ultrasound system
(Andover, Massachusetts). Increased forearm blood flow
was induced by inflating a blood pressure tourniquet around
the widest part of the forearm to a systolic blood pressure of
250 mm Hg for 4.5 min. Repeat brachial artery diameter
and blood flow scans were obtained immediately and 1 min
after tourniquet deflation. Resting brachial artery diameter
and blood flow scans were repeated 15 min later. Sublingual
nitroglycerin (NTG) (400 g) was administered, and final
scans were performed after 3 min.
The brachial artery was imaged in longitudinal section
2 cm to 15 cm above the elbow. Images were recorded using
the ultrasound digital storage and retrieval software system.
Vessel diameters were measured in triplicate using digital
calipers (MedArchive Viewer 2.1, Secure Archive, Boulder,
Colorado). Measurements were performed blinded to sub-
ject information and treatment group. The brachial artery
diameter was measured at end-diastole, using intima-media
interfaces or, if not well-visualized, media-adventitia
interfaces as landmarks. Flow-mediated vasodilation was
calculated as the ratio of the brachial artery diameter after
reactive hyperemia to the baseline diameter, expressed as a
percent change. Nitroglycerin-mediated vasodilation
(NTGMD) was calculated in an analogous fashion. Volu-
metric flow rates were calculated by multiplying the time
velocity integral of the angle-corrected Doppler flow signal
by the heart rate and the mean cross-sectional vessel area.
Changes in blood flow were expressed as percentages of
resting flow. In our laboratory, intraobserver reliability for
measurement of the brachial artery diameter is 0.987,
reflecting an interclass correlation coefficient across all
readings and conditions (30). Because of poor image quality,
data from two subjects in PAVES were excluded.
Statistical analysis. Clinical parameters included age, gen-
der, lipid values, heart rate and blood pressure. Brachial
artery reactivity parameters included brachial artery diame-
ter, FMD and NTGMD. Clinical and brachial artery
reactivity parameters were described by means and SD.
Outcome parameters included changes in lipid values,
brachial artery diameter, FMD and NTGMD. Changes
within groups were assessed by paired t tests. In PAVES,
between-group comparisons used t tests and chi-square
tests. Between studies comparisons used analysis of variance.
Changes in FMD, the primary end point, were evaluated
using the general linear mixed model for repeated measures,
controlling for changes in baseline diameter (SAS System
for Mixed Models, SAS Institute, Cary, North Carolina).
Bonferroni’s adjustment for multiple comparisons was per-
formed with a repeated measures contrast procedure. Pear-
son product-moment correlation coefficients described lin-
ear relationships between parameters. Predictors of FMD
were determined by linear forward step-wise regression
analyses. Based on published sample-size nomograms and
data from our laboratory, the number of subjects who
completed each study provided 90% power to detect a 2.5%
change in FMD within groups and 80% power to detect a
4% change in FMD between groups with an alpha of 0.05
(30,31).
RESULTS
Subject characteristics. STUDY 1—PAVES. Fifty-six subjects
participated in the placebo run-in period, after which eight
no longer met lipid criteria for randomization; three used
prohibited medications; one withdrew because of a rash, and
two withdrew for personal reasons. Of the 42 randomized
subjects, three subjects in group 1 and two subjects in group
2 withdrew within one month of randomization because of
side effects or for personal reasons. Accordingly, 37 subjects
were included in the final data analysis. The average age in
PAVES was 76.1  4.3 years (range 71 to 86 years) (Table
1). Hypertension was present in 83% of the subjects, and the
average systolic blood pressure was 145.4  18.9 mm Hg.
The most commonly used antihypertensive medications
were beta-adrenergic blocking agents (22%), calcium-
channel blockers (19%), diuretics (14%) and angiotensin-
converting enzyme (ACE) inhibitors (11%). Three subjects
(8%) were using estrogen replacement therapy. Use of these
medications was similar in each group, with the exception of
ACE inhibitors, which were more commonly used in group
1; however, two additional subjects in group 2 started ACE
inhibitors during the study. Five subjects started diuretics,
and three started beta-blockers. Dosages of vasoactive med-
ications did not change significantly during the study. No
subjects started estrogen replacement therapy. Subjects had
elevated total cholesterol (267.7 41.4 mg/dl) and LDL-C
(185.7  29.5 mg/dl) levels. Baseline characteristics and
lipid levels did not differ between groups (Table 1).
STUDY 2—SAVES. Twenty-one patients participated in the
placebo run-in period, after which one no longer met lipid
criteria for study continuation. Of the 20 subjects who
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started therapy, three withdrew because of side effects or for
personal reasons. Accordingly, 17 subjects were included in
the final data analyses. The average age in SAVES was
74.8  3.8 years (range: 70 to 82 years) (Table 1).
Hypertension was present in 71% of the subjects, and the
average systolic blood pressure was 147.8  22.7 mm Hg.
The most commonly used antihypertensive medications
were diuretics (29%), beta-blockers (18%) and calcium-
channel blockers (12%). Two subjects (12%) were using
estrogen replacement therapy. Dosages of vasoactive medi-
cations did not change significantly during the study. No
subjects started estrogen replacement therapy. One subject
started using an ACE inhibitor; one started a calcium-
channel blocker, and one started a beta-blocker. Subjects
had elevated total cholesterol (248.7  23.4 mg/dl) and
LDL-C (168.9  21.6 mg/dl) levels (Table 1). Baseline
subject characteristics and lipid levels did not differ between
studies (Table 1).
Changes in lipid levels. STUDY 1—PAVES. Vitamin E did
not affect lipid levels (Table 2). In group 1, pravastatin
reduced total cholesterol levels by 24%, LDL-C by 31%,
triglycerides by 23% and raised HDL-C levels by 4% (all
p  0.05) (Table 2). The increase in HDL-C levels
observed at 26 weeks no longer was statistically significant
after 52 weeks. Similar results were seen in group 2. Total
cholesterol (22%) and LDL-C (30%) levels decreased
(p  0.001), and HDL-C increased (5%, p  0.05) on
pravastatin.
STUDY 2—SAVES. Simvastatin therapy for 26 weeks reduced
total cholesterol levels by 24% (p  0.001) and LDL-C
levels by 36% (p  0.001) (Table 2). High-density lipopro-
Table 1. Baseline Subject Characteristics
PAVES
Group 1
PAVES
Group 2 P* SAVES P†
n 17 20 — 17 —
Age (yrs) 76.7  4.6 75.7  4.1 0.482 74.8  3.8 0.446
Women (n) 10 14 0.716 9 0.221
CHD (n) 5 4 0.506 3 0.685
Hypertension (n) 11 15 0.495 12 0.738
Diabetes mellitus (n) 0 1 0.380 1 0.649
Systolic blood pressure (mm Hg) 143.3  19.9 146.3  18.6 0.654 147.8  22.8 0.817
Total cholesterol (mg/dl) 274.0  51.9 262.7  31.1 0.423 248.7  23.4 0.150
LDL cholesterol (mg/dl) 189.6  36.8 182.6  22.6 0.486 168.9  21.6 0.100
HDL cholesterol (mg/dl) 48.9  8.8 51.3  12.3 0.519 53.8  13.9 0.504
Triglycerides (mg/dl) 170.6  96.2 144.4  58.9 0.321 130.4  48.2 0.251
Brachial artery diameter (mm) 4.5  0.9 3.8  0.8 0.037 4.3  0.7 0.047
Flow-mediated vasodilation (%) 0.1  3.5 3.1  4.2 0.027 3.2  3.1 0.023
Nitroglycerin-mediated vasodilation (%) 11.0  4.7 10.3  7.1 0.735 10.8  4.8 0.930
*PAVES group 1 vs. group 2; †PAVES (all subjects) vs. SAVES.
CHD  coronary heart disease; HDL  high-density lipoprotein; LDL  low-density lipoprotein; PAVES  Pravastatin and Vitamin E in Seniors study; SAVES 
Simvastatin, Ascorbate and Vitamin E in Seniors study.
Table 2. Lipid Values
PAVES–Group 1 Baseline
26 Weeks
(Pravastatin)
52 Weeks
(Pravastatin  Vitamin E)
Total cholesterol 274.0  51.9 207.7  38.2* 209.9  35.0*
LDL-C 189.6  36.8 131.1  29.7* 129.8  25.2*
HDL-C 48.9  8.8 50.5  10.5‡ 50.9  10.8
Triglycerides 170.6  96.2 130.6  67.2† 142.5  76.1‡
PAVES–Group 2 Baseline
26 weeks
(Vitamin E)
52 Weeks
(Pravastatin  Vitamin E)
Total cholesterol 262.7  31.1 267.5  42.5 209.0  26.4*
LDL-C 182.6  22.6 182.4  36.6 128.4  19.0*
HDL-C 51.3  12.3 51.6  13.1 54.2  12.8‡
Triglycerides 144.4  58.9 139.9  55.5 126.5  57.1
SAVES Baseline
26 Weeks
(Simvastatin)
52 Weeks
(Simvastatin  Vitamins C  E)
Total cholesterol 248.7  23.4 188.9  32.7* 197.3  16.6*
LDL-C 168.9  21.6 107.8  29.7* 117.5  15.9*
HDL-C 53.8  13.9 56.5  14.1 54.2  13.5
Triglycerides 130.4  48.2 122.6  54.5 123.8  54.5
*p  0.001 vs. baseline; †p  0.010 vs. baseline; ‡p  0.050 vs. baseline.
HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipoprotein cholesterol; PAVES  Pravastatin and
Vitamin E in Seniors study; SAVES  Simvastatin, Ascorbate and Vitamin E in Seniors study.
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tein cholesterol and triglyceride levels did not change
significantly (Table 2). Adding vitamins C and E did not
affect lipid levels. Reductions in total cholesterol and
LDL-C remained statistically significant after 52 weeks.
Brachial artery reactivity. Resting and reactive hyperemia
flow rates were similar and remained stable throughout both
studies (Table 3). At baseline, FMD did not correlate
significantly with total cholesterol, LDL-C, HDL-C or
triglycerides. Flow-mediated vasodilation on treatment and
changes in FMD did not correlate significantly with lipid
levels or their changes.
STUDY 1—PAVES. At baseline, subjects in both groups had
endothelial dysfunction characterized by impaired FMD of
the brachial artery (Table 3). Because subjects in group 1
had larger baseline brachial artery diameters (4.5  0.9 vs.
3.8  0.8 mm, p  0.037), FMD was lower in group 1
(0.1  3.5 vs. 3.1  4.2%, p  0.027, Table 1).
Accordingly, between-group comparisons of FMD were
adjusted for brachial artery diameter. In multivariate anal-
ysis, only brachial artery diameter and systolic blood pres-
sure predicted FMD. Nitroglycerin-mediated vasodilation
was similar in both groups (Table 3).
In group 1, the apparent increase in FMD (p  0.012)
after 26 weeks of pravastatin no longer was statistically
significant after adjusting for multiple comparisons (p 
0.093, Table 3). Nitroglycerin-mediated vasodilation also
did not change significantly (p  0.361). Adding vitamin E
to pravastatin did not affect FMD (p 0.586) or NTGMD
(p 0.510) significantly (Table 3). In group 2, therapy with
vitamin E for 26 weeks did not improve FMD (p  0.735)
or NTGMD (p  0.361) significantly (Table 3). The small
increase in FMD associated with the use of pravastatin was
not statistically significant (p  0.097), and NTGMD did
not change (p  0.434).
In comparisons between groups 1 and 2, the change in
FMD with pravastatin was not different from the change in
FMD with vitamin E, either at 26 weeks (p  0.444) or at
52 weeks (p  0.773).
STUDY 2—SAVES. At baseline, the average brachial artery
diameter was 4.3  0.7 mm, and subjects had impaired
FMD of the brachial artery (3.2 3.1%) (Table 3). After 26
weeks of therapy with simvastatin, FMD did not change
significantly (p  0.677) (Table 3). After 26 additional
weeks of simvastatin and the addition of vitamins C and E,
FMD still did not change (p  0.791). Over the entire 52
week treatment period, FMD did not change as compared
with baseline (p  0.958) (Table 3). Nitroglycerin-
mediated vasodilation did not change after 26 weeks of
therapy with simvastatin (p  0.341) or after 26 additional
weeks of simvastatin with vitamins C and E (p  0.444).
Accordingly, after 52 weeks, NTGMD did not change from
baseline (p  0.438) (Table 3).
Combined analyses. All of the prepravastatin (baseline
values from group 1 and 26 week values from group 2, n 
35) and postpravastatin (26-week values from group 1 and
52-week values from group 2, n 35) values were pooled to
Table 3. Brachial Artery Reactivity Data
PAVES—Group 1 Baseline
26 Weeks
(Pravastatin)
52 Weeks
(Pravastatin  Vitamin E)
Brachial artery diameter (mm) 4.5  0.9 4.2  0.9* 4.3  0.9*
Resting flow (ml/min) 59.7  35.5 57.9  37.8 57.4  25.1
FMD (%) 0.1  3.5 3.7  3.8†‡ 4.4  4.0§
Reactive hyperemia flow (ml/min) 321.4  156.0 298.9  154.5 292.3  133.1
NTGMD (%) 11.0  4.7 10.7  6.9 10.2  5.7
Post-NTG flow (ml/min) 77.7  30.7 70.4  29.2 65.9  25.5
PAVES—Group 2 Baseline 26 Weeks
(Vitamin E)
52 Weeks
(Pravastatin  Vitamin E)
Brachial artery diameter 3.8  0.8 3.9  0.8 3.8  0.8
Resting flow 45.1  23.7 50.4  34.0 51.9  26.0
FMD 3.1  4.2 2.6  4.1 5.3  4.8
Reactive hyperemia flow 264.9  113.5 227.4  80.3 282.0  128.6
NTGMD 10.3  7.1 12.4  5.7 10.7  5.0
Post-NTG flow 72.6  36.2 69.1  47.3 57.3  43.0
SAVES Baseline
26 Weeks
(Simvastatin)
52 Weeks
(Simvastatin  Vitamins C  E)
Brachial artery diameter 4.3  0.7 4.2  0.7 4.4  0.7
Resting flow 56.6  41.7 49.4  29.5 56.4  18.6
FMD 3.2  3.1 2.6  3.2 2.9  2.3
Reactive hyperemia flow 281.1  135.4 270.9  127.0 294.2  129.2
NTGMD 10.8  4.8 12.0  6.4 8.9  7.6
Post-NTG flow 57.2  26.1 59.8  26.9 50.2  21.7
*p  0.010 vs. baseline; †p  0.020 vs. baseline; ‡Padjusted  0.093 vs. baseline; §Padjusted  0.066 vs. baseline.
FMD  Flow-mediated dilation; NTG  nitroglycerin; NTGMD  nitroglycerin-mediated vasodilation; PAVES 
Pravastatin and Vitamin E in Seniors study; SAVES  Simvastatin, Ascorbate and Vitamin E in Seniors study.
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increase statistical power. In the pooled analysis from
PAVES, FMD improved from 1.4  4.0% to 4.6  4.3%;
however, after adjustment for repeated measures, this
change was not statistically significant (p  0.051). To
further increase statistical power, all of the pre- and
postsimvastatin (baseline and 26-week values from SAVES)
were added to the pooled analysis from PAVES (n  52).
Flow-mediated vasodilation increased slightly from 2.2 
3.9% to 2.9  3.7%; however, this change was not statisti-
cally significant (p  0.206).
DISCUSSION
Effects of antioxidant vitamins. In these studies, treat-
ment with vitamin E and the combination of vitamins C
and E for up to 52 weeks did not improve FMD of the
brachial artery in older adults with hypercholesterolemia,
either alone or in combination with statins. Previous studies
in middle-aged adults with hypercholesterolemia showed
variable effects of vitamin E supplementation on endothelial
function (20,21,23–28). Although oxidized breakdown
products of vitamin E may be atherogenic when adequate
levels of vitamin C are not present, the combination of
vitamins C and E did not improve FMD in our studies.
These findings are concordant with previous studies of this
combination of antioxidant vitamins in younger patients
with hypercholesterolemia (23) but are discordant with their
acute effects after a fatty meal in healthy adults (22).
Although use of vitamin C and E supplements was associ-
ated with a lower risk of total and coronary mortality in the
Established Populations for Epidemiologic Studies of the
Elderly (32), the results of the Heart Outcomes Prevention
Evaluation and GISSI-Prevenzione trials suggest that vita-
min E supplements do not reduce the incidence of future
coronary events in patients with, or at risk for, CHD
(33,34).
Effects of statins. In these studies, neither pravastatin nor
simvastatin improved FMD of the brachial artery, either
alone or in combination with antioxidant vitamins. Al-
though short-term pravastatin therapy improved FMD in
middle-aged adults with “average” and high cholesterol
levels, similar lipid reductions did not improve FMD in our
study of older adults (16,19). With one exception, subjects
in our study had higher total cholesterol and LDL-C levels
than previously investigated (16). In addition, our subjects
were older than those in previous studies of lipid-lowering
therapy and endothelial function. Our findings are concor-
dant with a recent report that six months of simvastatin
therapy did not improve coronary endothelial function in
patients with CHD (35); however, they are discordant with
another study in which simvastatin improved endothelial
function of the forearm vasculature in patients with mod-
erate hypercholesterolemia (18). That study, however, en-
rolled much younger subjects (mean age: 50  2 years) and
was only four weeks long. Although pravastatin and simva-
statin did not improve FMD in our studies, they do reduce
the incidence of adverse cardiovascular events in older adults
(36–38). Thus, the beneficial effects of lipid-lowering ther-
apy in older adults may be due to mechanisms other than
improving FMD, such as plaque stabilization, reduction in
inflammation or antithrombotic effects (39).
Effects of aging on vascular function. These studies are
the first clinical investigations of the effects of vitamin C,
vitamin E and lipid-lowering therapy on FMD in individ-
uals 70 years old. Our subjects were older than those in
previous investigations of these interventions on endothelial
function.
Aging, per se, is associated with endothelial dysfunction
(10–13). A 0.21%/year decline in FMD in men after age 40
years and a 0.49%/year decline in women after age 50 years
has been reported (11). Aging-related structural changes in
the vasculature, particularly in large- and medium-sized
arteries, may contribute to impaired vasodilation. With
aging, vessels lose distensibility as medial laminae and
elastin fibers are lost, and elastin is replaced with collagen
(12,40–42). Aging is also associated with reduced synthesis
and release of endothelium-derived nitric oxide, increased
activity of vasoconstrictive prostanoids, decreased diffusion
of nitric oxide to smooth muscle cells and increased degra-
dation of nitric oxide by oxygen-derived free radicals (12).
In both of our studies, NTGMD was lower than it was
in studies of younger subjects with and without hyper-
cholesterolemia. Nitroglycerin-mediated vasodilation did
not change with antioxidant vitamin or statin therapy. In
some studies, aging was not associated with impaired
endothelium-independent vasodilation (11–13); however,
in one of these studies, a negative trend was noted between
age and NTGMD (11). Other studies have demonstrated
inverse relationships between age and endothelium-
independent vasodilation in women but not in men
(14,43). In total, these studies included only six subjects
70 years old, the oldest of which was 73 years old (11,13).
Although NTGMD improved with aging in one study, it
only included two subjects 70 years old (44). Impaired
NTGMD suggests that aging-related structural changes
may lead to limited vasodilator reserve and may provide a
ceiling effect to the maximum ability of arteries to dilate
irrespective of endothelial function.
Study limitations. The brachial artery ultrasound tech-
nique for evaluating FMD is very sensitive and reproducible.
Although PAVES and SAVES were relatively small studies,
their sample sizes were larger than many published studies
addressing the effects of these interventions on FMD in
young and middle-aged adults. Their conclusions are
strengthened by a longer duration of treatment and because
each subject was used as his own control. Sample size
estimates were based on published nomograms for FMD
interventions and were verified using data from our labora-
tory (30,31). A small improvement in FMD (2.5%) with
pravastatin therapy cannot be excluded; however, in PAVES
the small increase in FMD observed with pravastatin was
not significant after adjusting for multiple comparisons, was
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not seen in subjects already receiving vitamin E and only
approached significance in the pooled group analysis. Fur-
thermore, an improvement in FMD was not seen with
simvastatin or in the combined analysis of both studies.
The dose of vitamin E used in these studies was less than
that used in some trials (range 300 to 1,600 IU) that
evaluated endothelial function in younger subjects; however,
in those studies, the dose of vitamin E was not associated
with the changes in endothelial function (20–28). Higher
doses of vitamin E or a different preparation may be needed
to demonstrate a treatment effect in older adults; however,
its combination with vitamin C had no effect in our subjects.
Plasma vitamin C and E levels were not measured, but the
dose and preparation of vitamin E we used significantly
reduced the in vitro oxidative susceptibility of LDL particles
isolated from older adults with CHD (63.9  9.8 years),
indicating that the vitamin E used in our studies is a potent
antioxidant (data unpublished). Furthermore, we verified
adherence by counting vitamin C and E capsules and pills at
each study visit.
Because the majority of our subjects had hypertension,
elevated systolic blood pressures may have masked an
improvement in FMD related to the interventions by
providing a ceiling to the maximum possible improvement
in FMD able to be achieved. Finally, impaired vasodilator
reserve in older hypercholesterolemic patients also may have
provided a ceiling to the maximum effectiveness of our
interventions. If so, this questions the validity of using the
brachial artery ultrasound technique for assessing endothe-
lial function in older adults.
Summary. Older adults with hypercholesterolemia have
impaired FMD of the brachial artery that does not improve
with lipid-lowering therapy, alone or in combination with
antioxidant vitamins. Because aging is associated with
morphologic and physiologic changes in the vascular wall,
the beneficial effects of lipid-lowering and antioxidant
vitamin therapies on flow-mediated arterial dilation previ-
ously observed in younger adults may not occur in older
adults. Reduced NTG-mediated arterial dilation in older
adults may reflect impaired vasodilator reserve.
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